A Pennsylvania report examining the role of pharmacy benefit managers (PBMs) in the state called for more transparency in how they do business managing Medicaid prescriptions.
A Pennsylvania report examining the role of pharmacy benefit managers (PBMs) in the state called for more transparency in how they do business managing Medicaid prescriptions.
Auditor General Eugene DePasquale said he wanted action to reduce Medicaid prescription costs and called for legislation to:
In 2017, Pennsylvania taxpayers paid $2.86 billion to PBMs for Medicaid enrollees, according to the state Department of Human Services, an increase of 100% in 4 years, up from $1.41 billion in 2013.
According to the report released this week, the practice of so-called “spread pricing”—the difference between what a plan sponsor is billed and a participating pharmacy is reimbursed—varies widely in the state. When Pennsylvania sought information on the practice, it found that 1 PBM made no money on spread pricing, since it relies only on administrative fees. Three PBMs made between $2 million and nearly $40 million on spread pricing, earning average profits between 28 cents and almost $13 per Medicaid prescription filled, the report said.
The report cited steps taken by other states to rein in PBMs, such as in Ohio and California.
Efforts to address PBMs did not make it out of Pennsylvania’s most recent legislative session, the auditor general said. At hearings DePasquale held earlier this year, he said dozens of pharmacists recalled how they began receiving letters from a larger pharmacy offering to buy their own pharmacies, citing declining reimbursement levels.
PBMs have been the subject of intense focus of scrutiny, from groups like the Community Oncology Alliance that are calling for more transparency, from attacks from patient representatives, and FDA Commissioner Scott Gottlieb, MD, and even getting called out in President Donald Trump’s plan to lower drug prices.
But it is at the state level, where Medicaid costs are split with the federal government, that PBM costs are also getting a new look.
In a statement, the Pharmaceutical Care Management Association (PCMA) criticized the report, saying that it failed to mention that “PBMs are reducing prescription drug costs and increasing access to needed treatments for the state’s most vulnerable population.”
“The Pennsylvania Auditor General’s report unfortunately is highly biased toward one special interest, the independent drugstore lobby. The report omits any mention of how PBMs are reducing prescription drugs costs and increasing access to needed medications for Pennsylvania’s Medicaid beneficiaries,” said JC Scott, PCMA president and chief executive office.
Without action, the state report said, PBMs can continue to not disclose whether they are reimbursing community pharmacists the same amount as their affiliated pharmacies for the same drugs; the total amount of business they do in a year; how they choose which prescription medications to cover; and how much profit they are make off of taxpayers.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen